|
| A) | non-prescribing. | ||
| B) | inadequate prescribing. | ||
| C) | continued prescribing despite evidence of ineffectiveness of opioids. | ||
| D) | All of the above |
Inappropriate opioid analgesic prescribing for pain is defined as the non-prescribing, inadequate prescribing, excessive prescribing, or continued prescribing despite evidence of ineffectiveness of opioids. Appropriate opioid prescribing is essential to achieve pain control; to minimize patient risk of abuse, addiction, and fatal toxicity; and to minimize societal harms from diversion. The foundation of appropriate opioid prescribing is thorough patient assessment, treatment planning, and follow-up and monitoring. Essential for proper patient assessment and treatment planning is comprehension of the clinical concepts of opioid abuse and addiction, their behavioral manifestations in pain patients, and how these potentially problematic behavioral responses to opioids both resemble and differ from physical dependence and pseudo-dependence [1,2]. Prescriber knowledge deficit has been identified as a key obstacle to appropriate opioid prescribing and, along with gaps in policy, treatment, attitudes, and research, contributes to widespread inadequate treatment of pain [1,3].
| A) | the highest safe dose. | ||
| B) | extended-release opioids. | ||
| C) | a quantity no greater than that needed for the expected duration of severe pain. | ||
| D) | All of the above |
CDC RECOMMENDATIONS FOR PRESCRIBING OPIOIDS FOR PAIN, EXCLUDING SICKLE CELL DISEASE OR CANCER, PALLIATIVE, OR END-OF-LIFE CARE
| Determining Whether or Not to Initiate Opioids for Pain | |||||
| |||||
| Selecting Opioids and Determining Opioid Dosages | |||||
| |||||
| Deciding Duration of Initial Opioid Prescription and Conducting Follow-Up | |||||
| |||||
| Assessing Risk and Addressing Harms of Opioid Use | |||||
|
| A) | Low | ||
| B) | Medium | ||
| C) | High | ||
| D) | Severe |
RISK STRATIFICATION FOR PATIENTS PRESCRIBED OPIOIDS
| Low Risk | ||||||||||
| ||||||||||
| Medium Risk | ||||||||||
| ||||||||||
| High Risk | ||||||||||
| ||||||||||
| HIV = human immunodeficiency syndrome, MRI = magnetic resonance imaging. |
| A) | consists of 5 items. | ||
| B) | is patient administered. | ||
| C) | diagnoses depression in the past month. | ||
| D) | assesses the likelihood of current substance abuse. |
The Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R) is a patient-administered, 24-item screen with questions addressing history of alcohol/substance use, psychologic status, mood, cravings, and stress. Like the ORT, the SOAPP-R helps assess risk level of aberrant drug-related behaviors and the appropriate extent of monitoring [28,29].
| A) | Analgesia | ||
| B) | Acceptance | ||
| C) | Affect (i.e., patient mood) | ||
| D) | Aberrant or abnormal drug-related behaviors |
When implementing a chronic pain treatment plan that involves the use of opioids, the patient should be frequently reassessed for changes in pain origin, health, and function [1]. This can include input from family members and/or the state PDMP. During the initiation phase and during any changes to the dosage or agent used, patient contact should be increased. At every visit, chronic opioid response may be monitored according to the "Five A's" [1,32]:
Analgesia
Activities of daily living (e.g., physical, psychological, and social functioning)
Adverse or side effects
Aberrant or abnormal drug-related behaviors
Affect (i.e., patient mood)
| A) | Have a plan for responding to unexpected results | ||
| B) | Explain to patients that toxicology testing will not be used punitively | ||
| C) | Explain expected results and ask patient if there may be unexpected results to be aware of | ||
| D) | All of the above |
Before ordering toxicology testing, including urine drug tests, clinicians should have a plan for responding to unexpected results and should explain to patients that toxicology testing will not be used punitively but instead is intended to improve their safety. Clinicians should also explain expected results and ask patients about use of prescribed medications and other substances and ask whether there might be unexpected results. This will provide an opportunity for patients to provide information about changes in their use of prescribed opioids or other drugs. Urine test results suggesting opioid misuse should be discussed with the patient using a positive, supportive approach. The test results and the patient discussion should be documented [2].
| A) | in their original container. | ||
| B) | by flushing down the toilet. | ||
| C) | using a take-back option in person or by mail. | ||
| D) | by offering or selling to others who need the medication. |
There are no universal recommendations for the proper disposal of unused opioids, although efforts toward patient education on what to do with unused or expired medications have increased . According to the FDA, the best way to dispose of most types of unused or expired medications (both prescription and over-the-counter) is to immediately use a take-back option, such as a designated "take-back location" or by mailing medications back using a prepaid drug mail-back envelope. As of April 2025, the FDA began requiring OA REMS Program Companies to provide prepaid mail-back envelopes upon request to pharmacies and other dispensers of opioid analgesics to improve proper and equitable disposal of this class of drugs [40].
| A) | a friend or relative. | ||
| B) | a prescription from one doctor. | ||
| C) | purchase from a drug dealer or other stranger. | ||
| D) | theft from a doctor's office, clinic, hospital, or pharmacy. |
Research has more closely defined the location of prescribed opioid diversion into illicit use in the supply chain from the manufacturer to the distributor, retailer, and the end user (the pain patient). This information carries with it substantial public policy and regulatory implications. The 2024 National Survey on Drug Use and Health found that 7.6 million individuals misused prescription opioids in the past year. Among persons 12 years of age or older, 42.3% obtained their prescription opioids from a friend or relative. Of this, 31.3% got them through a friend or relative for free, 6.9% bought them from a friend or relative, and 4% took them from a friend or relative without asking. Another 40.5% got their opioids through a prescription from one doctor. Less frequent sources included a drug dealer or other stranger (7.6%) and theft from a doctor's office, clinic, hospital, or pharmacy (1.3%) [49].
| A) | Asking for specific medications | ||
| B) | Injecting medications meant for oral use | ||
| C) | Reluctance to decrease opioid dosing once stable | ||
| D) | Stockpiling medications during times when pain is less severe |
In addition to aberrant urine screens, there are certain behaviors that are suggestive of an emerging opioid use disorder. The most suggestive behaviors are [53,54]:
Selling medications
Prescription forgery or alteration
Injecting medications meant for oral use
Obtaining medications from nonmedical sources
Resisting medication change despite worsening function or significant negative effects
Loss of control over alcohol use
Using illegal drugs or non-prescribed controlled substances
Recurrent episodes of:
Prescription loss or theft
Obtaining opioids from other providers in violation of a treatment agreement
Unsanctioned dose escalation
Running out of medication and requesting early refills
Behaviors with a lower level of evidence for their association with opioid misuse include [53,54]:
Aggressive demands for more drug
Asking for specific medications
Stockpiling medications during times when pain is less severe
Using pain medications to treat other symptoms
Reluctance to decrease opioid dosing once stable
In the earlier stages of treatment:
Increasing medication dosing without provider permission
Obtaining prescriptions from sources other than the pain provider
Sharing or borrowing similar medications from friends/family
| A) | Institutes of Medicine | ||
| B) | U.S. Drug Enforcement Administration | ||
| C) | Office of National Drug Control Policy | ||
| D) | U.S. Department of Health and Human Services |
The U.S. Drug Enforcement Administration (DEA) is responsible for formulating federal standards for the handling of controlled substances. In 2011, the DEA began requiring every state to implement electronic databases that track prescribing habits, referred to as PDMPs. Specific policies regarding controlled substances are administered at the state level [60].
| A) | LAAM | ||
| B) | Naloxone | ||
| C) | Methadone | ||
| D) | Buprenorphine |
In response to acute overdose, the short-acting opioid antagonist naloxone is considered the criterion standard, and it remains the most widely used opioid antagonist for the reversal of overdose and opioid-related respiratory depression. It acts by competing with opioids at receptor sites in the brain stem, reversing desensitization to carbon dioxide, and reversing or preventing respiratory failure and coma. There is no evidence that subcutaneous, intramuscular, or nasal inhalation use is inferior to intravenous naloxone. As such, this has prompted naloxone to be available to the general public over-the-counter for administration outside the healthcare setting to treat acute opioid overdose in all 50 states [77].
| A) | LAAM. | ||
| B) | naloxone. | ||
| C) | methadone. | ||
| D) | buprenorphine. |
The three primary treatment modalities used for detoxification are opioid agonists, non-opioid medications, and rapid and ultra-rapid opioid detoxification. The most frequently employed method of opioid withdrawal is a slow, supervised detoxification during which an opioid agonist, usually methadone, is substituted for the abused opioid. Methadone is the most frequently used opioid agonist due to the convenience of its once-a-day dosing. Methadone is highly bound to plasma proteins and accumulates more readily than heroin in all body tissues. Methadone also has a longer half-life, approximately 22 hours, which makes withdrawal more difficult than from heroin. Substitution therapy with methadone has a high initial dropout rate (30% to 90%) and an early relapse rate. Alternative pharmacologic detoxification choices (all off-label) include clonidine (with or without methadone), midazolam, trazodone, or buprenorphine [32,71,80,81,82].
| A) | an emphasis on total abstinence. | ||
| B) | spiritual growth, personal responsibility, and helping other addicts. | ||
| C) | the viewpoint that opioid abuse and dependence is a chronic, progressive disease. | ||
| D) | All of the above |
Twelve-step programs for opioid abuse and dependence include Narcotics Anonymous (NA) and Methadone Anonymous (MA) and are modeled after Alcoholics Anonymous (AA), an abstinence-based support and self-improvement program that is based on the 12-step model of recovery. AA has helped hundreds of thousands of individuals with alcohol misuse disorder achieve sobriety [93]. The 12-step model emphasizes acceptance of dependence as a chronic, progressive disease that can be arrested through abstinence but not cured. Additional elements include spiritual growth, personal responsibility, and helping other addicted persons. By inducing a shift in the consciousness of the addict, 12-step programs offer a holistic solution and are a resource for emotional support [93]. Although research on efficacy and patient outcomes in NA and MA is very limited, many prominent researchers emphasize the important role that ongoing involvement in 12-step programs plays in recovery from substance abuse [94].